Circulating Tumor DNA in Oncology

When somatic cells in the human body undergo apoptosis or necrosis, released DNA enters bloodstream. This type of is called cell-free (cfDNA). In patients with cancer, from tumor circulating (ctDNA), which carries genetic alterations specific to cells. recent years, ctDNA has attracted particular attention terms concept liquid biopsy cancer care. Conventionally, tissue required for definitive diagnosis and imaging examinations, such as CT, are performed evaluating recurrence residual lesions. Although treatment burden on being slightly reduced due advances medicine, invasive examinations medical exposure still unavoidable. addition, prognosis varies considerably depending degree progression at time detection. Therefore, early detection utmost importance. With increase health consciousness, more people regular checkups, it becomes necessary diagnose a larger number an earlier stage. accuracy been improved by new tests examination techniques, each organ must be examined separately, some organs difficult examine than others checkup. The process screening, diagnosis, after extensive. It can also expensive, may invasive. If all these processes replaced analysis biopsy, only single blood sample required. Under circumstances, various studies currently progress use clinical practice approach that greatly reduce burden. We present overview current situation ctDNA, well its future issues prospects.